The administration of CB therapy triggers early death in breast cancer cells, as evidenced by upregulation of cleaved caspase 3, downregulation of Bcl2 and survivin, an elevation of reactive oxygen species (ROS), and disruption of mitochondrial membrane potential. The gene discussed is BIRC5; the disease is breast carcinoma.